January 10, 2017/Neurosciences

Drugs for Pediatric Migraines Found to Be No Better Than Placebo

Amitriptyline and topiramate had adverse side effects


A randomized, double-blind trial on the use of two drugs commonly used to treat migraine headaches found similar efficacy to placebo in reducing headaches in children and adolescents but significantly more side effects. These findings of the Childhood and Adolescent Migraine Prevention (CHAMP) trial were published in the October 27, 2016, issue of the New England Journal of Medicine.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Until now, there has been no good evidence that children with migraines benefit from drugs used for the same condition in adults,” says Ethan Benore, PhD, Cleveland Clinic psychologist and Director of Outpatient Services in the Center for Pediatric Chronic Pain. “The CHAMP trial was very well designed and answers many questions.”

Study design and findings

More than 300 children and adolescents with migraine aged 8 to 17 years participated in the study, which was conducted at 31 sites in the United States, including Cleveland Clinic. Participants were randomized to either daily amitriptyline (target goal, 1 mg/kg), topiramate (target goal, 2 mg/kg) or placebo. Doses were increased over a period of eight weeks until the target was reached. The total treatment period was 24 weeks.

The primary endpoint was a 50 percent reduction in headache days over the last 28-day period of the trial compared with the baseline 28-day period, based on a daily headache diary kept by participants. Secondary outcomes included headache-related disability, number of headache days and serious adverse events.

No significant differences were found for the primary outcome among the arms, which occurred in 52 percent of those taking amitriptyline, 55 percent in the topiramate group and 61 percent in the placebo group. Likewise, no significant differences were found for secondary outcome benefits among treatment arms.

However, rates of adverse events did differ significantly. More fatigue and dry mouth occurred in the amitriptyline group versus placebo, and more paresthesias and weight loss in the topiramate group versus placebo. Three patients in the amitriptyline group had altered mood, and one patient taking topiramate attempted suicide.

The study was ended early owing to futility in finding that either medication was more effective than placebo over a period of 24 weeks.

Strong placebo effect

The high placebo response found in the study was similar to rates reported in other headache and pain trials. Reasons for this have never been well-explained, according to A. David Rothner, MD, Director of the Pediatric/Adolescent Headache Program at Cleveland Clinic.

“We have known for years that placebo is a powerful tool,” Dr. Rothner says. “We cannot literally provide a placebo pill in practice but I do try to employ the effect by other means.”

Dr. Rothner explains that he reassures patients with migraines that they do not have a life-threatening disease and that they will get better by following a prescribed treatment plan.

Best practice recommendations

Dr. Rothner often recommends the following for patients with chronic migraines:

  • A healthy diet with six 8-ounce glasses of water daily
  • Eliminating caffeine, chocolate, luncheon meat, aged cheese and MSG
  • A regular sleep schedule, including eight hours of sleep
  • Supplements of magnesium, riboflavin, enzyme Co-Q10 and butterbur
  • Stress and pain management techniques


He also refers patients to Dr. Benore and his colleague, Kate Eshleman, PsyD, of the Center for Pediatric Behavioral Health, for a program of evidence-based behavioral treatment, which targets daily health behaviors, and relaxation and stress management training.

Dr. Rothner also judiciously prescribes medications for some patients, which, he points out, are effective in more than half of patients, as confirmed by the CHAMP trial.


Related Articles

pills, syringes and vials on a tabletop
May 15, 2024/Neurosciences/Podcast
Multiple Sclerosis Medications: Making the Most of a Multitude of Options (Podcast)

Insights on the decision process for selecting a treatment approach

neurosurgeon performing minimally invasive spine operation
Top Takeaways From the 2024 AANS Annual Meeting

Scientific program chair reflects on what may resonate longest from this year’s neurosurgery conference

central vein sign on a brain MRI
CAVS-MS Advances Quest to Improve the Diagnosis of Multiple Sclerosis

New reports focus on neuroimaging biomarkers and features of atypical presentations

doctor applying force to patient's forearm to test strength
Offering Rehabilitation Care to Oncology Patients (Podcast)

New oncologic rehab program is tailored to managing the effects of cancer and its treatments

vial of blood labeled "neurofilament light chain"
Could Serum Neurofilament Light Chain Level Help Guide MS Management?

Perhaps, with caveats: sNfL elevation has low sensitivity and lags MRI activity by at least a month

brain puzzle with piece missing and female symbol
Latest WAM Grant Recipients Take on Alzheimer’s Disease in Women Across Multiple Fronts

Awards fund research on oxidative targets, immunometabolism, spatial navigation testing and more

sleepless woman looking at clock
Sleep Apnea and Insomnia Are Highly Prevalent and Linked to Disease Worsening in Neuropsychiatric Disorders

Large cohort study suggests need for routine sleep screening as part of neurological care

neuron affected by neuromyelitis optica
Novel Monoclonal Antibodies for NMOSD Show Strong Efficacy and Safety in Real-World Study

Early experience with the agents confirms findings from clinical trials